Labcorp Holdings Inc. filings document a public laboratory-services company with common stock listed on the New York Stock Exchange under LH. Its 8-K reports cover operating results, financial guidance, dividend declarations, board appointments, and material definitive agreements tied to financing arrangements.
Labcorp's regulatory record also includes proxy materials describing board composition, committee service, executive compensation, equity awards, shareholder voting matters and governance practices. Debt and liquidity-related filings disclose senior unsecured term-loan terms, receivables purchase arrangements, covenants and related obligations, while earnings exhibits detail results across the company's diagnostics and biopharma laboratory services activities.
Labcorp Holdings Inc. executive Bryan T. Vaughn reported equity awards granted on February 10, 2026. He received non-qualified stock options on 2,200 shares of common stock at an exercise price of $284.5 per share, vesting in three equal annual installments starting on that grant date and expiring on February 9, 2036.
He was also granted 730 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this RSU grant, Vaughn directly holds 4,354 Restricted Stock Units in total.
Labcorp Holdings Inc. chief financial officer Julia Aijun Wang received new equity awards. On February 10, 2026, she was granted 7,100 non-qualified stock options with an exercise price of $284.50 per share and 2,350 restricted stock units.
The options vest in three equal annual installments starting on the grant date and are exercisable until February 9, 2036. The restricted stock units also vest in three equal annual installments beginning on February 10, 2027, with each unit delivering one share of Labcorp common stock.
Labcorp Holdings Inc. reported that SVP and Chief Accounting Officer Peter J. Wilkinson acquired new equity awards on February 10, 2026. He received non-qualified stock options for 1,300 shares of common stock with an exercise price of $284.5 per share, granted under the 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on that grant date and expire on February 9, 2036.
Wilkinson was also granted 440 Restricted Stock Units, each representing one share of common stock, vesting in three equal annual installments beginning on February 10, 2027. Following this grant, he holds 2,664 Restricted Stock Units in total, all reported as directly owned.
Labcorp Holdings Inc. executive Akinbolade Oyegunwa reported new equity awards. On 02/10/2026, the EVP, CIO & CTO acquired 2,400 non-qualified stock options with an exercise price of $284.5 per share under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.
The options vest in three equal annual installments beginning on 02/10/2026 and are exercisable until 02/09/2036. On the same date, Oyegunwa also received 810 Restricted Stock Units, each representing one share of common stock, which will vest in three equal annual installments beginning on February 10, 2027. Following this grant, Oyegunwa holds 2,420 Restricted Stock Units in total.
Labcorp Holdings Inc. executive Amy B. Summy, EVP and Chief Marketing Officer, reported new equity awards on February 10, 2026. She received 1,900 non-qualified stock options with an exercise price of $284.50 per share under the 2025 Omnibus Incentive Plan. These options vest in three equal annual installments starting on the grant date and cover 1,900 shares of common stock.
She also acquired 620 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this grant, she directly holds 1,534 RSUs in total. The filing reflects routine compensation-related awards rather than open-market purchases or sales.
Labcorp Holdings Inc. executive Anita Z. Graham, EVP and Chief Human Resources Officer, reported equity awards granted on February 10, 2026. She received non-qualified stock options for 4,100 shares of common stock with an exercise price of $284.5 per share, vesting in three equal annual installments beginning that date. She was also granted 1,360 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this award, she holds 2,757 Restricted Stock Units in total.
Labcorp Holdings Inc. executive Megan D. Bailey reported equity awards received on February 10, 2026. She was granted 3,300 non-qualified stock options with a $284.5 exercise price under the 2025 Omnibus Incentive Plan, vesting in three equal annual installments starting on that grant date.
She was also granted 1,100 Restricted Stock Units, each representing one share of common stock, which vest in three equal annual installments beginning on February 10, 2027. After this grant, she directly holds 3,300 stock options and 3,230 Restricted Stock Units.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, received new equity awards. On February 10, 2026 he was granted 6,100 non-qualified stock options with an exercise price of $284.5 per share, vesting in three equal annual installments beginning February 10, 2027.
He was also granted 2,020 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in three equal annual installments starting February 10, 2027. After this grant, he holds 6,100 options and 4,910 RSUs directly.
Labcorp Holdings Inc. director Garheng Kong reported an equity award of restricted stock units. On February 10, 2026, Kong acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock. These units vest fully on February 10, 2027.
Following this grant, Kong beneficially owns 1,670 Restricted Stock Units, held directly. This filing reflects a stock-based compensation award rather than an open-market purchase or sale.
Labcorp Holdings Inc. director Paul Rothman reported an equity award in the form of Restricted Stock Units. On February 10, 2026, he acquired 733 Restricted Stock Units as a grant, each representing the right to receive one share of Labcorp common stock if vesting conditions are met.
These Restricted Stock Units vest fully on February 10, 2027. Following this grant, Rothman beneficially holds a total of 1,670 Restricted Stock Units in a direct ownership capacity, aligning his compensation more closely with the company’s future share performance.